1. Chronic Rhinosinusitis

2. This program will include a discussion of off-label treatments and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal

3. CRS: Overview

4. CRS: Cost to Society

5. How Is CRS Defined? AAO-HNS Criteria

6. How Is CRS Defined? US/Canadian/European Criteria

7. Medical Management of CRS

8. Goals of Topical Therapy for CRS

9. Delivery Methods for Intranasal Therapies

10. Challenges of Topical Drug Delivery in CRS

11. Challenges of Topical Drug Delivery Acute Maxillary Sinus in Unoperated Patient

12. Challenges of Topical Drug Delivery Nasal Polyps

13. CT Scan Findings Consistent With CRS

14. CT Scans Before and After Surgery for Nasal Polyps

15. Distribution of Topical Agents to the Sinuses Meta-Analysis

16. Distribution of Topical Agents to the Sinuses Meta-Analysis (cont)

17. Endoscopic Sinus Surgery

18. Nasal Cavity Before and After Surgery to Remove Polyps

19. Saline Nasal Irrigation

20. Head Position Is Important for Nasal Irrigation

21. Model of Nasal Irrigation Pre-Surgery

22. Model of Nasal Irrigation Pre- and Postsurgery

23. Topical Steroids

24. Topical Steroids (cont)

25. Topical Antibiotics

26. Steroid-Eluting Nasal Stents

27. Steroid-Eluting Nasal Stent RESOLVE Study

28. SINUVA Nasal Stent

29. Steroid-Eluting Nasal Stent RESOLVE II Study

30. Novel Spray Device Exhalation Delivery System

31. EDS-FLU NAVIGATE Trials

32. EDS-FLU NAVIGATE I and II Integrated Results

33. EDS-FLU NAVIGATE Trials -- AEs

34. Concluding Remarks

35. Abbreviations